Diseases - Publications - Faculty & Research - Harvard Business School

Filter Results: (299)

Filter Results: (299)

Show Results For

← Page 3 of 299 Results →

Sort by

Are you looking for?

→Search All HBS Web

January 2024
Article

Cost of Exempting Sole Orphan Drugs from Medicare Negotiation

By: Matthew Vogel, Olivia Zhao, William B. Feldman, Amitabh Chandra, Aaron S. Kesselheim and Benjamin N. Rome

Importance: The Inflation Reduction Act (IRA) requires Medicare to negotiate prices for some high-spending drugs but exempts drugs approved solely for the treatment of a single rare disease.
Objective: To estimate Medicare spending and global... View Details

Keywords: Health Care and Treatment; Insurance; Price; Health Industry

Find at Harvard

May 2021
Case

Colombia: An Economic Premium to Peace?

By: Richard H.K. Vietor

Colombia, once the fastest growing country in Latin America, continues to struggle with productivity. Both labor productivity and total factor productivity have been low for the past decade, despite economic growth of 4.7% annually. Many factors contribute, which... View Details

January 2023 (Revised September 2024)
Supplement

The END Fund (B)

By: V. Kasturi Rangan and Courtney Han

Founded in 2012, the END fund focused on eliminating five Neglected Tropical Diseases that accounted for 80% of the tropical diseases affecting nearly 1.5 billion people worldwide. Its roughly $25 million/year annual budget was fully committed when it got news that the... View Details

Keywords: Health Disorders; Investment Funds; Global Range; Nonprofit Organizations; Resource Allocation; Decisions; Health Care and Treatment; Mission and Purpose

January 2020
Case

Celata Bioinnovations

By: John R. Wells and Benjamin Weinstock

In December 2019, Jon Hu (HBS ‘19) and Dr. Samantha Dale Strasser, co-founders of Celata Bioinnovations, were raising $1 million to launch their company. They had founded Celata less than six months earlier with the aim of redefining the drug discovery process.... View Details

January – February 2008
Article

The Dangers of Wishful Thinking

By: Richard S. Tedlow and David Ruben

Too many U.S. businesses (including tires, super-markets, and information technology) have been infected with the disease of denial. The answer? In Lincoln's words, “We must disenthrall ourselves.” View Details

Keywords: Knowledge Acquisition; Knowledge Use and Leverage; Leadership; Growth and Development Strategy; Success; Behavior; Cognition and Thinking

Find at Harvard

June 2023 (Revised July 2024)
Case

Biogen and the Aduhelm Melee

By: Amitabh Chandra and Lauren Gunasti

Alzheimer's Disease is a devastating condition affecting millions of Americans. At this time, there is no cure. In 2021, Biogen's Aduhelm (aducanumab) received FDA approval under the accelerated approval pathway after a controversial approval process.

This... View Details

Keywords: Health Testing and Trials; Governing Rules, Regulations, and Reforms; Valuation; Product Development; Pharmaceutical Industry

21 Nov 2005
Research & Ideas

The Geography of Corporate Giving

Why companies support nonprofits and other socially responsible activities is an intriguing question for both academics and practitioners. After all, there is no clear-cut evidence that corporate "do-gooding" results in greater returns for shareholders. In an... View Details

Keywords: by Sean Silverthorne

15 Jun 2020
Research & Ideas

A Mass Crisis Can Overwhelm Health Care. Liberia Found a Solution.

quickly and efficiently for COVID-19 in the US, he says. The training modules cover four areas including epidemic surveillance; maternal and child health care; identifying Malaria, tuberculosis, and HIV; and referrals and chronic disease... View Details

Keywords: by Rachel Layne; Health

May 2018 (Revised January 2019)
Teaching Note

Nashton Partners and Its Search Fund Process

By: Richard S. Ruback, Royce Yudkoff and Ahron Rosenfeld

Teaching Note for HBS No. 212-006. In 2008, Jay Davis (HBS’ 08) and Jason Pananos (HBS’ 08) formed Nashton Partners and raised $500,000 from investors to fund their search. After 30 months of searching, and exhausting the money they raised to fund their search, Davis... View Details

Keywords: Search Fund; Acquisition; Capital Structure; Financing and Loans; Investment Funds; Partners and Partnerships

11 Jun 2019
Working Paper Summaries

Throwing the Baby Out with the Drinking Water: Unintended Consequences of Arsenic Mitigation Efforts in Bangladesh

Keywords: by Nina Buchmann, Erica Field, Rachel Glennerster, and Reshmaan Hussam

August 2001 (Revised April 2003)
Case

International Trachoma Initiative

By: Diana Barrett, James E. Austin and Sheila McCarthy

In an effort to combat trachoma, a major eye disease, the Clark Foundation entered into a partnership with Pfizer Pharmaceuticals. After a successful pilot project, a joint initiative was established (the Trachoma initiative) that has as its goal to eradicate the... View Details

Keywords: For-Profit Firms; Joint Ventures; Globalization; Mission and Purpose; Organizational Culture; Alliances; Partners and Partnerships; Non-Governmental Organizations; Health Industry

Find at Harvard

2020
Working Paper

What Can Economics Say About Alzheimer's Disease?

By: Amitabh Chandra, Courtney Coile and Corina Mommaerts

Alzheimer’s Disease (AD) affects one in ten people aged 65 or older and is the most expensive disease in the United States. We describe the central economic questions raised by AD. While there is overlap with the economics of aging, the defining features of the... View Details

Keywords: Health Disorders; Health Care and Treatment; Economics

February 2000
Case

E2M Health Services

By: Richard M.J. Bohmer and Naomi Atkins

Outlines the growth of an innovative diabetes disease management organization from 1994-99. Having demonstrated the success of their model in managing diabetes populations in Texas and New York State, the CEO and president must decide the future strategy of the company... View Details

Keywords: Business Model; Customer Focus and Relationships; Decision Choices and Conditions; Financial Markets; Revenue; Innovation and Invention; Business or Company Management; Marketing Strategy; Internet; Health Industry

June 2023
Case

Verve Therapeutics: Taking DNA Editing to Heart

By: Shikhar Ghosh and Shweta Bagai

Verve Therapeutics, a public biotech company based in Boston, created a novel approach to addressing cardiovascular disease (CVD) - a leading cause of deaths globally. The company's approach was a single shot treatment to permanently lower cholesterol, thus reducing... View Details

Keywords: AI; Genetic Engineering; Medicine; Health Care and Treatment; Genetics; Innovation Strategy; Business and Stakeholder Relations; Medical Specialties; Innovation and Invention; Entrepreneurship; Biotechnology Industry

February 2024
Case

Best Buy Health: Enabling Care at Home

By: Robert S. Huckman, Rosabeth Moss Kanter, Antonio Moreno, Bradley Staats and Sarah Mehta

This case explores retailer Best Buy’s decision to enter health care. Best Buy Health aims to enable care at home across three prongs: consumer health, active aging, and virtual care. A key pillar of Best Buy Health's strategy is leveraging the Geek Squad—the company's... View Details

Keywords: Business Ventures; Health Care and Treatment; Innovation and Invention; Business Strategy; Market Entry and Exit; Service Delivery; Service Operations; Electronics Industry; Health Industry; Retail Industry; United States; Minnesota

June 2020
Case

Breakthroughs at Blueprint Medicines

By: Richard G. Hamermesh, Kathy Giusti and Susie L. Ma

Precision medicine company Blueprint Medicines was building a successful track record for bringing drug therapies to market 40% faster than average. The company had spent $40 million dollars and two years building a compound library that became its drug development... View Details

Keywords: Precision Medicine; Cancer; Biotechnology; Drug Development; Strategy; Expansion; Science; Genetics; Information Technology; Entrepreneurship; Organizational Culture; Management; Growth and Development; Pharmaceutical Industry; United States; Cambridge; Massachusetts

June 2004 (Revised November 2004)
Case

Acorda Therapeutics: Rebuilding the Spinal Cord

Acorda is an early-stage life science start-up with a promising product that is close to reaching the market (Phase III clinical trials). The company is grappling with how to expand its portfolio of molecules to make the business more sustainable. It faces classic... View Details

Keywords: Decision Making; Science-Based Business; Health Testing and Trials; Business Startups; Product Development; Biotechnology Industry

Find at Harvard

22 Sep 2020
Working Paper Summaries

Older People Are Less Pessimistic about the Health Risks of COVID-19

Keywords: by Pedro Bordalo, Katherine B. Coffman, Nicola Gennaioli, and Andrei Shleifer

09 Jun 2020
Working Paper Summaries

Aggregate and Firm-Level Stock Returns During Pandemics, in Real Time

Keywords: by Laura Alfaro, Anusha Chari, Andrew Greenland, and Peter K. Schott

October 2014 (Revised September 2017)
Case

The National Football League and Brain Injuries

By: Richard G. Hamermesh and Matthew G. Preble

The National Football League (NFL) was both the most popular spectator sport in the U.S. and a major economic entity, taking in roughly $10 billion a year in revenue. However through the early twenty-first century, an increased understanding of the long-term effects of... View Details

Keywords: Employee Safety; Safety; Employees; Sports; Health; Ethics; Sports Industry; United States

←
3
4
…
14
15
→